Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and AZD6738 in IDH Mutant Solid Tumors
NCT03878095Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, ceralasertib in solid tumor, cholangiocarcinoma (CCA), sponsored by National Cancer Institute. Started Jan 2020; status: active, not recruiting.
02
Drugs
olaparibceralasertib
03
Conditions
solid tumorcholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03878095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878095.